S95035
/ Servier
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
May 27, 2026
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
(clinicaltrials.gov)
- P1/2 | N=60 | Active, not recruiting | Sponsor: Servier Bio-Innovation LLC | N=342 ➔ 60 | Trial completion date: Oct 2031 ➔ May 2027 | Trial primary completion date: Oct 2031 ➔ May 2027 | Recruiting ➔ Active, not recruiting
Enrollment change • Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDKN2A • MTAP
April 30, 2026
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
(clinicaltrials.gov)
- P1/2 | N=342 | Recruiting | Sponsor: Servier Bio-Innovation LLC | Active, not recruiting ➔ Recruiting | N=104 ➔ 342
Enrollment change • Enrollment open • First-in-human • Esophageal Cancer • Gastric Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDKN2A • MTAP
April 27, 2026
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
(clinicaltrials.gov)
- P1/2 | N=104 | Active, not recruiting | Sponsor: Servier Bio-Innovation LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • First-in-human • Esophageal Cancer • Gastric Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDKN2A • MTAP
February 18, 2026
CL1-95035-001: A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP
(clinicaltrialsregister.eu)
- P1/2 | N=118 | Recruiting | Sponsor: Institut De Recherches Internationales Servier IRIS
New P1/2 trial • Esophageal Cancer • Gastric Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MTAP
June 17, 2025
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
(clinicaltrials.gov)
- P1/2 | N=308 | Recruiting | Sponsor: Servier Bio-Innovation LLC | Phase classification: P1 ➔ P1/2 | N=27 ➔ 308 | Trial completion date: May 2026 ➔ Oct 2031 | Trial primary completion date: May 2026 ➔ Oct 2031
Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
November 04, 2024
TRIAL IN PROGRESS: An open label phase I multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
(COSA 2024)
- P1 | "Identification of predictive biomarkers and changes from baseline in intra-tumoral concentrations of SAM and MTA are key exploratory endpoints of the study. Clinical trial information (NCT06188702)"
Clinical • Metastases • P1 data • Oncology • Solid Tumor • MAT2A • MTAP
May 02, 2024
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
(clinicaltrials.gov)
- P1 | N=27 | Recruiting | Sponsor: Servier Bio-Innovation LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor
January 03, 2024
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
(clinicaltrials.gov)
- P1 | N=27 | Not yet recruiting | Sponsor: Servier Bio-Innovation LLC
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 8
Of
8
Go to page
1